Galapagos NV has provided an update on the ongoing strategic review of its cell therapy business, announcing that its Board of Directors has recently received a limited number of non-binding offers to acquire the division from consortia primarily composed of financial investors. The board initiated the review earlier this year, exploring all possible alternatives—including divestiture—with the aim of preserving shareholder value and positioning its cell therapy operation for future growth.
Interested parties have been granted access to confidential presentations and a comprehensive data room as part of their due diligence process. Galapagos continues to work closely with potential buyers to ensure financing commitments are secured, including supporting fundraising efforts when appropriate. The company expects the deadline for submission of binding and fully financed offers to occur in the coming weeks.
Once binding proposals are received, the Board plans to quickly decide whether to proceed with a sale or consider alternative strategies. Galapagos has stated that final outcomes from the strategic review will be disclosed no later than November 5, 2025, alongside its third-quarter financial results. As a pan-European biotechnology leader, Galapagos is committed to developing innovative, best-in-class medicines for high unmet medical needs, with its decentralized cell therapy platform remaining central to its strategic objectives.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!